AXIM BIOTECHNOLOGIES, INC.
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|
| Revenue | $47.1K | $49.1K | $0 | $21.7K | $43.3K | $10.0K | — |
| Cost of Revenue | $154.1K | $50.4K | $0 | — | — | — | — |
| Gross Profit | $-107.1K | $-1.2K | $0 | — | — | — | — |
| Gross Margin | -227.5% | -2.5% | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $235.6K | $571.5K | $0 | — | — | — | — |
| SG&A Expense | $3.4M | $9.5M | $505.7K | — | — | — | — |
| Operating Income | $-3.8M | $-10.0M | $-505.7K | — | — | — | — |
| Operating Margin | -7,988.8% | -20,451.3% | — | — | — | — | — |
| Interest Expense | $275.7K | $43.2K | $32.5K | — | — | — | — |
| Pretax Income | $-5.8M | $-10.1M | $-538.3K | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | — | — | — | — |
| Net Income | $-5.8M | $-10.1M | $-582.9K | $-89.2K | $-14.9K | $-2.8K | — |
| Net Margin | -12,346.0% | -20,539.2% | — | -411.8% | -34.4% | -27.9% | — |
| EPS (Basic) | $-0.17 | $-0.27 | $-0.02 | $0.00 | — | $0.00 | — |
| EPS (Diluted) | $-0.17 | $-0.27 | $-0.02 | $0.00 | — | $0.00 | — |
| Shares Outstanding (Basic) | 52.5M | 39.6M | 33.0M | 33.0M | 33.0M | — | 20.0M |
| Shares Outstanding (Diluted) | 52.5M | 39.6M | 33.0M | 33.0M | 33.0M | 23.3M | 20.0M |
| Dividends Per Share | — | — | — | — | — | — | — |